Stryker Corporation $SYK Shares Purchased by Tyche Wealth Partners LLC

Tyche Wealth Partners LLC increased its stake in shares of Stryker Corporation (NYSE:SYK) by 155.7% during the 4th quarter, Holdings Channel.com reports. The fund owned 2,670 shares of the medical technology company’s stock after purchasing an additional 1,626 shares during the quarter. Tyche Wealth Partners LLC’s holdings in Stryker were worth $938,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Natural Investments LLC raised its stake in Stryker by 6.2% during the 4th quarter. Natural Investments LLC now owns 2,879 shares of the medical technology company’s stock worth $1,011,000 after acquiring an additional 168 shares in the last quarter. Oak Ridge Investments LLC raised its stake in Stryker by 4.7% during the 4th quarter. Oak Ridge Investments LLC now owns 33,543 shares of the medical technology company’s stock worth $11,789,000 after acquiring an additional 1,505 shares in the last quarter. Optima Capital LLC acquired a new stake in Stryker during the 4th quarter worth $79,000. Norris Perne & French LLP MI raised its stake in Stryker by 1.6% during the 4th quarter. Norris Perne & French LLP MI now owns 45,860 shares of the medical technology company’s stock worth $16,118,000 after acquiring an additional 707 shares in the last quarter. Finally, Tectonic Advisors LLC increased its stake in Stryker by 1.6% in the fourth quarter. Tectonic Advisors LLC now owns 1,976 shares of the medical technology company’s stock valued at $694,000 after purchasing an additional 32 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SYK has been the topic of a number of recent research reports. Needham & Company LLC lifted their price objective on shares of Stryker from $448.00 to $454.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Barclays restated an “overweight” rating and issued a $469.00 price objective on shares of Stryker in a research note on Monday, February 2nd. UBS Group dropped their price objective on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 17th. Raymond James Financial upgraded shares of Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price objective on the stock in a research note on Tuesday, January 6th. Finally, Citizens Jmp upgraded shares of Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 price objective on the stock in a research note on Friday, December 19th. Fifteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $421.74.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the sale, the director owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.60% of the company’s stock.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker signed a definitive agreement to acquire Amplitude Vascular Systems, adding a next?generation intravascular lithotripsy (IVL) platform to its peripheral vascular portfolio — a strategic product bolt?on that expands Stryker’s vascular addressable market and supports future growth expectations. Read More.
• Positive Sentiment: Leerink Partners initiated coverage with an “Outperform” rating and a $410 price target (?18% upside vs. the cited $347 price), signaling incremental analyst support for Stryker’s growth trajectory and likely encouraging buy?side interest. Read More.
• Positive Sentiment: BTIG reaffirmed a “Buy” rating and set a $397 price target (?14% upside), providing another analyst endorsement that supports near?term upside and investor confidence. Read More.
• Neutral Sentiment: Stryker restored affected systems after a reported cyberattack; while restoration reduces immediate operational risk, the incident has prompted investors to weigh cybersecurity exposure and potential remediation costs when assessing valuation and execution risk. Read More.

Stryker Stock Performance

Shares of NYSE:SYK traded up $3.61 during midday trading on Tuesday, hitting $350.85. The stock had a trading volume of 180,304 shares, compared to its average volume of 2,038,256. The company has a market capitalization of $134.37 billion, a PE ratio of 41.73, a P/E/G ratio of 1.98 and a beta of 0.92. The stock has a 50 day moving average price of $354.45 and a two-hundred day moving average price of $360.24. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. Stryker Corporation has a 1 year low of $319.32 and a 1 year high of $404.87.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating the consensus estimate of $4.40 by $0.07. The business had revenue of $7.17 billion for the quarter, compared to the consensus estimate of $7.12 billion. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The business’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $4.01 earnings per share. As a group, equities analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. Stryker’s payout ratio is currently 41.90%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.